News

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

The data, which included information from more than 10 million adults collected over 20 years, lend credence to a long-held theory in the field.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 14, 2022.

The clinical psychologist at Cleveland Clinic provided insight on the tricky nature of diagnosing a patient with nonepileptic seizures and the difficult conversations that can ensue. [WATCH TIME: 3 minutes]

The authors noted that the findings indirectly support the use of highly effective disease-modifying treatments from the early stages of disease in those with pediatric-onset MS, even in the absence of persistent physical disability.

The neurocritical care fellow at Massachusetts General Hospital and Brigham and Women’s Hospital discussed findings from a recent study that evaluated patients with COVID-19 and disorders of consciousness. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne-Maree Kelly, MD, MClinEd, FACEM. [LISTEN TIME: 23 minutes]

Jennifer Frontera, MD, professor of neurology, NYU Langone Grossman School of Medicine, discussed findings from a recently published study investigating neurological complications in hospitalized patients with COVID-19.

Despite not providing additional, clinically relevant benefit for patients with amyotrophic lateral sclerosis as an add-on to standard therapy, the intravenous treatment was feasible and well tolerated.

AUPN Leading Edge Episode 3 features Clifton Gooch, MD, and Rich Sobieray, who discuss expectations for chairs in the academic health systems. [LISTEN TIME: 37 minutes]

Only 30% of the observed cohort of more than 150 children had their hypertonia type specified as spasticity and/or dystonia by age 5 years, highlighting a need for additional education efforts.

Outlining the findings from a recent study comparing SAGE to the Mini-Mental State Examination, the director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center stressed the importance of identifying patients at-risk for dementia early on. [WATCH TIME: 6 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The results of a phase 4 study demonstrate the efficacy of APOKYN® (apomorphine hydrochloride injection) treatment.

The Anavex Life Sciences treatment was found to be well tolerated in all cohorts of healthy patients with no serious adverse events reported. It is in development for conditions such as frontotemporal dementia.

Reflecting on 2021, Mitzi Joi Williams, MD, the founder and CEO of Joi Wellness Group MS Center discussed the positive repercussions of the COVID-19 pandemic, which allowed for more freedom when sharing data.

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed benefits of both the pen-and-paper and digital assessments. [WATCH TIME: 7 minutes]

Although both are dopamine reuptake inhibitors, those on MAO-B inhibitors demonstrated greater mean PDQ-39 mobility scores and EuroQol 5-dimension 3-level scores over a median of 4.5 years.

The director of the Joseph Epstein Center for Emergency Medicine Research discussed whether years of experience causes variation in the way migraine is diagnosed and treated in an emergency department setting. [WATCH TIME: 2 minutes]

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed why MR fingerprinting holds significant clinical potential in epilepsy and epilepsy-related disorders.

The Centers for Medicare and Medicaid Services issued a proposed decision memo detailing the coverage criteria for patients with Alzheimer disease to be covered by the federal health insurance platform when administered aducanumab (Aduhelm; Biogen).

Mitzi Joi Williams, MD, founder and CEO of Joi Wellness Group Multiple Sclerosis Center, shared her thoughts on changes to the MS care model over the past year, as well as how the pandemic and telehealth have affected care for underrepresented populations.

The noninvasive vagus nerve stimulation device showed results consistent with what had been previously observed in the literature, with a particular benefit observed for those who have migraine with aura.

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed motivations behind creating the pen-and-paper test, as well as its digital companion. [WATCH TIME: 2 minutes]

Episode 17 of the AUPN Leadership Minute features Rohit Das, MD, of UT Southwestern Medical Center; and Clifton L. Gooch, MD, of the University of South Florida. [WATCH TIME: 7 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Roth, PhD. [LISTEN TIME: 12 minutes]

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]

Darcy Krueger, MD, PhD, director, Tuberous Sclerosis Clinic, Cincinnati Children’s, discussed the idea behind swiftly treating tuberous sclerosis at infant stages using targeted therapeutic approaches.